The Genzyme ALF facility is a fully operational GMP manufacturing facility that produces a critical life-saving drug for patients suffering from Gaucher's disease. As worldwide demand for this product is extremely high, Genzyme cannot afford to slow down or delay manufacturing operations.
Dore + Whittier has played a key role in assisting the Allston Landing Facility navigate through multiple complex construction projects that are a result of regulatory requirements, ongoing maintenance, and plant upgrades.
In Dore + Whittier's role as an Owner's Project Manager, we oversee all aspects of these projects from initial concept through design, bidding, Guaranteed Maximum Price (GMP), Change Control Request (CCR), Commissioning Qualification and Validation (CQV), implementation, and closeout.
Our goal is to work seamlessly with multiple Genzyme departments to coordinate and facilitate a smooth project implementation, while ensuring that manufacturing operations are not interrupted at any point. Simply put, the projects we complete are like working on a car engine while it's running.
Over the past few years we have overseen dozens of projects that have all been planned, constructed, and closed out with no unplanned impacts on Genzyme's manufacturing operations. We feel the reason we have been so successful is due to our commitment to safety, planning, teamwork, communication, quality, and client satisfaction.
Owner Genzyme, a Sanofi Company